Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): alpha L Idosiduronase

            Therapeutic Area: Genetic Disease Product Name: JR-171

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 30, 2020

            Details:

            In this study, MPS I patients will be treated with JR-171 for at most 12 weeks to evaluate the safety of JR-171 as the primary endpoint and exploratory efficacy and pharmacokinetics as secondary endpoints.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): alpha L Idosiduronase

            Therapeutic Area: Genetic Disease Product Name: JR-171

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 31, 2020

            Details:

            JR-171 is a blood-brain-barrier (BBB)-penetrating recombinant α-L-iduronidase, the product candidate for the treatment of patients with MPS I, to which J-Brain Cargo®, JCR’s proprietary BBB penetration technology, is applied.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LentiGlobin

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Bluebird bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 21, 2020

            Details:

            The two subsidiaries, Hitachi Chemical Advanced Therapeutics Solutions (HCATS) and Apceth Biopharma, will be in charge of late-clinical development and manufacturing of LentiGlobin at facilities in Germany (Apceth) and the U.S. (HCATS).